# Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM

> **NCT07020949** · PHASE1 · COMPLETED · sponsor: **Tonghua Dongbao Pharmaceutical Co.,Ltd** · enrollment: 49 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** THDBH120 injection
- **DRUG:** Placebo of THDBH120 injection

## Key facts

- **NCT ID:** NCT07020949
- **Lead sponsor:** Tonghua Dongbao Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-13
- **Primary completion:** 2024-11-27
- **Final completion:** 2024-11-27
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07020949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07020949, "Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07020949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*